Revvity Competitive Intelligence & Landscape

Revvity provides end-to-end solutions designed to empower scientists, researchers, and clinicians in addressing global health challenges [https://jobs.revvity.com/].

Revvity offers a diverse range of products and services, evidenced by its investor relations activities and online shop. The company's investor relations page provides access to quarterly results, including webcasts, press releases, and presentations [https://ir.revvity.com/home/default.aspx]. Furthermore, Revvity operates an online web shop where customers can access exclusive pricing, manage orders, and track shipments [https://www.revvity.com/contact-us]. They also have an Omics portal for clinical genomics and newborn screening services [https://www.revvity.com/contact-us]. It is important to note that Revvity and PerkinElmer are now separate companies with distinct offerings, and all Revvity-related information is exclusively found on revvity.com [https://www.revvity.com/frequently-asked-questions].

The target market for Revvity includes scientists, researchers, and clinicians worldwide who are engaged in solving significant health challenges [https://jobs.revvity.com/]. The company operates on a global scale, with many colleagues working remotely while also maintaining offices and sites across the world [https://jobs.revvity.com/Our-sites].

Revvity's headquarters are located in Waltham, Massachusetts [https://ir.revvity.com/news/investor-news/news-details/2023/Launching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure/default.aspx].

With a team exceeding 11,000 colleagues globally, Revvity combines the dynamism of an industry disruptor with the extensive experience of a long-standing leader in its field [https://jobs.revvity.com/]. The company's mission is to power innovation from discovery to cure, leveraging its expertise in life sciences and diagnostics to make a tangible impact on lives everywhere [https://ir.revvity.com/news/investor-news/news-details/2023/Launching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure/default.aspx].

For more specialized offerings, Revvity Omics laboratory provides genetic testing services, including Whole Exome Sequencing (WES) and Whole Genome Sequencing as a clinical service, alongside Newborn Screening packets for conditions like Lysosomal Storage Disorders and Severe Combined Immunodeficiency [Revvity.com/omics-billing-information, Revvity.com/category/whole-exome-sequencing, apps-omics.revvity.com/product-catalog/newborn-screening/, Revvity.com/de-en/category/whole-genome-sequencing]. Billing information for these services is available through Revvity Omics. Customers can also manage orders and access results for clinical genomics or newborn screening services via a dedicated Revvity Omics portal account [Revvity.com/category/single-site-analysis, Revvity.com/de-en/category/whole-genome-sequencing].

Revvity's pricing strategy also encompasses annual adjustments for Evergreen Service Plans and automatically renewed Service Plans [Revvity.com/policies/terms-conditions-of-service]. Beyond testing, Revvity provides Genomics Software, including LIMS, DNA analysis, and interpretation modules, designed to meet the high computational demands of DNA sequencing [resources.revvity.com/pdfs/bro-ngs-software-brochure-digital.pdf]. By logging into a Revvity.com account, customers gain access to their specific pricing, facilitate re-ordering, and benefit from priority order processing and dynamic order tracking [Revvity.com/category/single-site-analysis, Revvity.com/de-en/category/whole-genome-sequencing].

Notable job openings indicate a significant investment in software and AI talent, including roles such as Senior Front End Software Developer (AI, React, JavaScript) - Remote US, Associate Backend Software Engineer (Java, Vert.x, AWS) - Remote US, and Lead Software Architect/Engineer - AI Native (Remote US) [https://jobs.revvity.com/job/waltham/senior-front-end-software-developer-ai-react-javascript-remote-us/20539/95647953536, https://jobs.revvity.com/job/waltham/associate-backend-software-engineer-java-vert-x-aws-remote-us/20539/94612991936, https://jobs.revvity.com/job/boston/lead-software-architect-engineer-ai-native-remote-us/20539/87482229472]. This suggests a push towards developing advanced, AI-driven solutions for the life sciences sector.

Beyond software, Revvity is also actively recruiting for roles that support its core operations and sales growth, such as Quality Control Associate I, Bottling Coordinator, Territory Account Manager- Informatics Solutions, NA-East Region, and Sr. Sales Specialist [https://jobs.revvity.com/en/search-jobs, https://jobs.revvity.com/en/job/-/-/20539/92727758896]. The presence of positions like Senior Program Director, ERP Solutions, and International Trade Compliance Specialist further highlights an emphasis on robust infrastructure and global operational efficiency [https://jobs.revvity.com/en/search-jobs, https://jobs.revvity.com/en/job/waltham/senior-program-director-erp-solutions/20539/87557149056]. While specific information regarding layoffs for Revvity (revvity.com) is not available in the provided sources, the consistent number and variety of job postings across multiple functions point to a company in an active growth and development phase. These hiring patterns align with Revvity's stated mission as a developer and provider of end-to-end solutions aimed at addressing global health challenges, demonstrating an expansion of its team to meet these ambitious goals [https://jobs.revvity.com/job/boston/senior-project-manager/20539/95023638736].

Looking into the first quarter of 2026, Revvity reported revenues of $711 million, with pro forma revenue at $687 million, reflecting 7% revenue growth and 3% organic growth (6% pro forma organic growth). GAAP EPS from continuing operations was $0.37, while adjusted EPS from continuing operations reached $1.06. The company also announced its intention to divest its China Immunodiagnostics business during this quarter and updated its full-year 2026 guidance Revvity Announces Financial Results for the First Quarter of 2026.

Earlier in 2025, Revvity reported $699 million in revenue for the third quarter, showing 2% reported growth and 1% organic growth. GAAP EPS was $0.40, with an adjusted EPS from continuing operations of $1.18. During this period, the company reaffirmed its full-year 2025 organic growth and raised its adjusted EPS guidance, along with authorizing a new $1 billion share repurchase program Revvity Announces Financial Results for the Third Quarter of 2025. For the first quarter of 2025, Revvity posted $665 million in revenue, a 2% reported growth and 4% organic growth, with GAAP EPS of $0.35 and adjusted EPS from continuing operations of $1.01 Revvity Announces Financial Results for the First Quarter of 2025. These figures demonstrate Revvity's consistent focus on financial health and shareholder value through growth and strategic financial management.

Beyond investor events, Revvity engages with the scientific community by participating in significant industry gatherings like ASGCT 2025 in New Orleans from May 13–17, where they will host a booth and a welcome party [source]. They also list the CCMG & Garrod 2026 Joint Conference and CYTO as upcoming events [source]. Additionally, the company holds quarterly earnings conference calls for investors [source].

Revvity is also committed to empowering its customers through comprehensive training programs. They offer various formats, including on-demand, instructor-led, and virtual instructor-led customer training to help users maximize their solutions in life sciences and diagnostics [source]. Furthermore, Revvity provides expert-led training designed to deepen understanding of their products and their practical applications [source].